

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Study of Single and Combination Medication Treatment of Tinnitus by Alprazolam and Fluoxetine

#### Protocol summary

##### Study aim

determine the efficacy Single and Combination Medication Treatment of Tinnitus by Alprazolam and Fluoxetine

##### Design

In this research, 147 patients with tinnitus referring to Amirmomenin hospital were chosen purposefully and a code was allocated to each one of them. Then, patients were randomly divided into two control and intervention groups.

##### Settings and conduct

patients with chronic, non-pulsatile tinnitus (taking more than six months) will be participated in the study. An informed consent of the patients participating in the study will be obtained after giving a detailed explanation about the study. For all participants, audiometric testing will be requested before treatment and again a week after four weeks of treatment. Patients will be informed to refer to the study's designated physician in the hospital in case of fever, sore throat, rash, unusual bruising and bleeding. Patients will randomly be divided into four groups based on a random table: Group 1: Fluoxetine Group 2: Alprazolam + Fluoxetine Group 3: Placebo

##### Participants/Inclusion and exclusion criteria

Patients with 20-65 years of age; Tinnitus history taking at least six months; Exclusion Criteria: Acute or chronic middle ear infections; History of thyroid and rheumatologic diseases; History of occupational exposure to noise; Concomitant use of other drugs;

##### Intervention groups

Group 1: Fluoxetine Group 2: Alprazolam + Fluoxetine Group 3: Placebo

##### Main outcome variables

Tinnitus

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20080831001138N26**  
Registration date: **2018-02-17, 1396/11/28**  
Registration timing: **registered\_while\_recruiting**

Last update: **2018-02-17, 1396/11/28**

Update count: **0**

##### Registration date

2018-02-17, 1396/11/28

##### Registrant information

##### Name

Fataneh Bakhshi

##### Name of organization / entity

Guilan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 13 1223 8307

##### Email address

entrc@gums.ac.ir

##### Recruitment status

##### Recruitment complete

##### Funding source

Guilan University of Medical Science, Vice Chancellor for Research

##### Expected recruitment start date

2017-12-22, 1396/10/01

##### Expected recruitment end date

2018-12-22, 1397/10/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Study of Single and Combination Medication Treatment of Tinnitus by Alprazolam and Fluoxetine

**Public title**

Tinnitus treatment with single or combination medication

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients with 20-65 years of age Tinnitus history taking at least six months

**Exclusion criteria:**

Acute or chronic middle ear infections History of thyroid and rheumatologic diseases History of occupational exposure to noise Concomitant use of other drugs

**Age**

From **20 years** old to **65 years** old

**Gender**

Both

**Phase**

4

**Groups that have been masked**

- Participant
- Investigator
- Outcome assessor

**Sample size**

Target sample size: **147**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

According to the study's inclusion, the patients with tinnitus are assigned to three groups by random block method. Before the study, the permutations are designed manually. 24 sextuple blocks with different permutations and a triple block of ABP are placed in a sealed envelope. Then, the blocks will be randomly taken out of the envelope, when the patients refer gradually to reach the sample size of 147. The envelopes are put in another room (research center), and a third party notifies the members about it.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In order to maintain double blindness in the study, both patients and all researchers will be unaware of the received drug.( A researcher will explain about the drug to the patients and record data, and another researcher will evaluate the patients). Drugs will look completely similar in shape, color and size. The patients will be divided into three groups according to the Random Number Table.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Guilan University of Medical Sciences

**Street address**

vice-chancellor for Research Building, opposite of Sepah Bank,Shahid Beheshti Blvd

**City**

Raht

**Province**

Guilan

**Postal code**

4139637459

**Approval date**

2017-07-29, 1396/05/07

**Ethics committee reference number**

IR.GUMS.REC.1395.185

**Health conditions studied****1****Description of health condition studied**

Tinnitus

**ICD-10 code**

H93.1

**ICD-10 code description**

Tinnitus

**Primary outcomes****1****Description**

Tinnitus

**Timepoint**

Starting Time, Fifth week

**Method of measurement**

TSI Questionnaire and VAS Score

**Secondary outcomes****1****Description**

Anxiety

**Timepoint**

Starting Time(time0), Fifth Week

**Method of measurement**

Beck Anxiety Inventory (BAI)

**2****Description**

Depression

**Timepoint**

Starting Time(time0), Fifth Week

**Method of measurement**  
Beck Depression Inventory

## Intervention groups

### 1

**Description**  
Alprazolam: Daily taking of 0.5 mg till the end of the fourth week of treatment

**Category**  
Treatment - Drugs

### 2

**Description**  
Oxcarbazepine: In the first week, its initial nightly dose will be 300 mg. After the second week until the end of the fourth week, the treatment will be continued with daily dose of 600 mg.

**Category**  
Treatment - Drugs

### 3

**Description**  
Fluoxetine: In the first week, its initial daily dose will be 20 mg. After the second week until the end of the fourth week, the treatment will be continued with daily dose of 50 mg.

**Category**  
Treatment - Drugs

## Recruitment centers

### 1

**Recruitment center**  
**Name of recruitment center**  
Guilan University of Medical Sciences  
**Full name of responsible person**  
Dr Alia Saberi  
**Street address**  
Amiralmomenin Hospital, 17 Shahrivar Ave, Emam Khomeini Ave  
**City**  
Rasht  
**Province**  
Guilan  
**Postal code**  
4139637459  
**Phone**  
+98 13 3322 5242  
**Email**  
ent\_rc@yahoo.com

## Sponsors / Funding sources

### 1

**Sponsor**  
**Name of organization / entity**

Rasht University of Medical Sciences  
**Full name of responsible person**  
Susan Komae  
**Street address**  
Shahid Beheshti Blvd.(west), opposite of Sepah Bank, vice-chancellor for Research Building, Rasht,  
**City**  
Rasht  
**Province**  
Guilan  
**Postal code**  
4139637459  
**Phone**  
+98 13 3333 0959  
**Email**  
research@gums.ac.ir

**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**

Yes  
**Title of funding source**  
Rasht University of Medical Sciences  
**Proportion provided by this source**

100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

**Contact**  
**Name of organization / entity**  
Rasht University of Medical Sciences  
**Full name of responsible person**  
Dr Alia Saberi  
**Position**  
Associate Professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Neurology  
**Street address**  
Amiralamomenin Hospital, 17 shahrivar St  
**City**  
Rasht  
**Province**  
Guilan  
**Postal code**  
4139637459  
**Phone**  
+98 13 3322 5242  
**Fax**  
**Email**  
a\_saberi@gums.ac.ir  
**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Dr Alia Saberi

**Position**

Associate Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Neurology

**Street address**

Amiralamomenin Hospital, 17 shahrivar St

**City**

Rasht

**Province**

Guilan

**Postal code**

4139637459

**Phone**

+98 13 3322 5242

**Fax****Email**

a\_saberi@gums.ac.ir

**Web page address**

Master

**Other areas of specialty/work**

Health Service Management

**Street address**

Amiralamomenin Hospital, 17 shahrivar St

**City**

Rasht

**Province**

Guilan

**Postal code**

4139637459

**Phone**

+98 13 3322 5242

**Fax****Email**

fatemeh\_nezamdoust@yahoo.com

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Not applicable

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

## Person responsible for updating data

### Contact

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Fatemeh Nezamdoust

**Position**

Msc

**Latest degree**